Lung Cancer Clinical Trial

Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

Summary

A study to evaluate the safety of Nivolumab in participants with advanced or metastatic non-small cell lung cancer

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Non small cell lung cancer (Squamous or non-squamous)
At least one prior anti-cancer therapy that did not work
ECOG Performance Scale 0-1

Exclusion Criteria:

Cancer that has spread to the brain or leptomeninges unless there is no evidence of progression by MRI for 8 weeks after treatment is complete and within 28 days before first dose of study drug
Active, known or suspected autoimmune disease or infection
Prior immuno-oncology therapy
Corticosteroids within 2 weeks of study drug administration

Other protocol defined inclusion/exclusion criteria could apply

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

129

Study ID:

NCT03090737

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

Alabama Oncology
Birmingham Alabama, 35205, United States
Los Angeles Hematology Oncology Medical Group
Los Angeles California, 90017, United States
St Vincent Frontier Cancer Center
Billings Montana, 59102, United States
Broome Oncology
Johnson City New York, 13790, United States
Guthrie Medical Group Sayre
Sayre Pennsylvania, 18840, United States
Local Institution - 0015
Kingston Ontario, K7L 2, Canada
Local Institution - 0014
Oshawa Ontario, L1G 2, Canada
Local Institution - 0001
Toronto Ontario, M5G 2, Canada
Local Institution - 0017
Nagoya Aichi, 46486, Japan
Local Institution - 0023
Osaka-shi Osaka, 54185, Japan
Local Institution - 0018
Koto-ku Tokyo, 13585, Japan
Local Institution - 0016
Tokyo , 10400, Japan
Local Institution - 0003
Craiova , 20034, Romania
Local Institution - 0006
Sector 2 , 02232, Romania
Local Institution - 0011
Port Elizabeth Eastern Cape, 6045, South Africa
Local Institution - 0013
Parktown, Johannesburg Gauteng, 2193, South Africa
Local Institution - 0012
George Western CAPE, 6530, South Africa

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

129

Study ID:

NCT03090737

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.